Work

190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

Year: 2016

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/s1556-0864(16)30299-4

Authors: K. Park, J.-Y. Han, D.-W. Kim, L.A. Bazhenova, S.-H. Ou, Y.-K. Pang, H.S. Hin, O. Juan, J. Son, P. Jänne

Institutions: Samsung Medical Center, Sungkyunkwan University, National Cancer Center, National Cancer Center Hospital, Seoul National University, Seoul National University Hospital, Moores Cancer Center, University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, University of Malaya, International Islamic University Malaysia, Hospital Universitari i Politècnic La Fe, Hanmi Pharmaceutical (South Korea), Dana-Farber Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2339550548

FWCI: 3.187

Cites:

Cited by: 15

Related to: 10